Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
All times are local (Market data is delayed by at least 15 minutes).

Transactions by ELI LILLY & CO (LLY) in the last 6 months

Announced 11/21/14
15.00M for Zosano Pharma Corporation
Private Placement

Zosano Pharma Corporation (NasdaqCM:ZSAN) announced that it has entered into common stock purchase agreement with new investor, Eli Lilly and Company for a private placement of 1,363,636 common shares at $11 per share for gross proceeds of $15,000,000 on November 21, 2014. The shares to be issued in the transaction have a par value of $0.0001 per share. The company paid fees of $525,000 equal to 3.5% in connection with the transaction. The company will issue securities ...
Read More


LLY's price was unchanged after the transaction was announced on 11/21/14.
Investor / Buyer
Eli Lilly and Company
Legal Advisor
Foley Hoag LLP
 
Announced 10/27/14
410.00M for Eli Lilly and Company, United States Veterinary Products
Merger/Acquisition

Virbac SA (ENXTPA:VIRP) entered into an agreement to acquire United States Veterinary products from Eli Lilly and Company (NYSE:LLY) on October 27, 2014. Under the terms of this agreement, Virbac would acquire a combination of titles and rights for the United States on trademarks, marketing authorizations, patents, know-how, customer lists and other assets, related to two major parasiticides, Sentinel®Flavor Tabs and Sentinel® Spectrum. The transaction is subject to ...
Read More


LLY's price was unchanged after the transaction was announced on 10/27/14.
Investor / Buyer
Virbac SA
Creditor / Lender
Eli Lilly and Company
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:FP €0.00 EUR 0.00

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $162.59 USD +2.04
AstraZeneca PLC 4,686 GBp -5.00
Bristol-Myers Squibb Co $65.26 USD +0.26
Novo Nordisk A/S kr369.70 DKK +34.70
Teva Pharmaceutical Industries Ltd $61.98 USD -0.44
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 33.1x
Price/Sales 4.0x
Price/Book 5.1x
Price/Cash Flow 34.2x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.